Free Trial
NYSE:RCUS

Arcus Biosciences (RCUS) Stock Price, News & Analysis

Arcus Biosciences logo
$10.62 +0.06 (+0.52%)
Closing price 03:59 PM Eastern
Extended Trading
$10.61 -0.01 (-0.05%)
As of 06:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Arcus Biosciences Stock (NYSE:RCUS)

Key Stats

Today's Range
$10.53
$10.96
50-Day Range
$7.94
$10.58
52-Week Range
$6.50
$18.98
Volume
633,062 shs
Average Volume
1.01 million shs
Market Capitalization
$1.13 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.14
Consensus Rating
Moderate Buy

Company Overview

Arcus Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

RCUS MarketRank™: 

Arcus Biosciences scored higher than 48% of companies evaluated by MarketBeat, and ranked 598th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Arcus Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Arcus Biosciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about Arcus Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Arcus Biosciences are expected to decrease in the coming year, from ($3.15) to ($4.73) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Arcus Biosciences is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Arcus Biosciences is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Arcus Biosciences has a P/B Ratio of 2.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Arcus Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    13.81% of the float of Arcus Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Arcus Biosciences has a short interest ratio ("days to cover") of 8.9.
  • Change versus previous month

    Short interest in Arcus Biosciences has recently decreased by 10.75%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Arcus Biosciences does not currently pay a dividend.

  • Dividend Growth

    Arcus Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.81% of the float of Arcus Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Arcus Biosciences has a short interest ratio ("days to cover") of 8.9.
  • Change versus previous month

    Short interest in Arcus Biosciences has recently decreased by 10.75%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Arcus Biosciences has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Arcus Biosciences this week, compared to 6 articles on an average week.
  • Search Interest

    8 people have searched for RCUS on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Arcus Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.60% of the stock of Arcus Biosciences is held by insiders.

  • Percentage Held by Institutions

    92.89% of the stock of Arcus Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Arcus Biosciences' insider trading history.
Receive RCUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RCUS Stock News Headlines

INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.tc pixel
Arcus (RCUS) Q2 Revenue Jumps 310%
See More Headlines

RCUS Stock Analysis - Frequently Asked Questions

Arcus Biosciences' stock was trading at $14.89 at the beginning of the year. Since then, RCUS stock has decreased by 28.7% and is now trading at $10.6150.

Arcus Biosciences, Inc. (NYSE:RCUS) announced its quarterly earnings results on Wednesday, August, 6th. The company reported ($1.11) EPS for the quarter, topping analysts' consensus estimates of ($1.14) by $0.03. Arcus Biosciences's revenue was up 310.3% compared to the same quarter last year.

Arcus Biosciences (RCUS) raised $99 million in an IPO on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO.

Arcus Biosciences' top institutional investors include Geode Capital Management LLC (1.51%), Sofinnova Investments Inc. (1.14%), Bank of America Corp DE (0.47%) and Hudson Bay Capital Management LP (0.40%). Insiders that own company stock include Gilead Sciences, Inc, Terry J Rosen, Juan C Jaen, Jennifer Jarrett, Robert C Goeltz II, Carolyn C Tang, Yasunori Kaneko and Alexander Azoy.
View institutional ownership trends
.

Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arcus Biosciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
8/06/2025
Today
8/28/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:RCUS
CIK
1724521
Fax
N/A
Employees
500
Year Founded
N/A

Price Target and Rating

High Price Target
$33.00
Low Price Target
$13.00
Potential Upside/Downside
+99.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.17)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$283 million
Net Margins
-109.56%
Pretax Margin
-109.19%
Return on Equity
-55.96%
Return on Assets
-25.73%

Debt

Debt-to-Equity Ratio
0.18
Current Ratio
4.50
Quick Ratio
4.50

Sales & Book Value

Annual Sales
$258 million
Price / Sales
4.36
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.16 per share
Price / Book
2.05

Miscellaneous

Outstanding Shares
106,430,000
Free Float
96,214,000
Market Cap
$1.13 billion
Optionable
Optionable
Beta
0.89

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NYSE:RCUS) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners